Viral infections evidence library
Hepatitis B
A living PubMed evidence library for acute and chronic hepatitis B, antiviral therapy, monitoring, complications, prevention, and emerging cure research.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Living evidence synopsis
What the current PubMed collection shows.
Alexandria currently organizes 0 non-retracted PubMed-indexed records for Hepatitis B. The structured collection includes 0 guideline or consensus records, 0 evidence syntheses/systematic reviews/meta-analyses, and 0 randomized or phase III studies. 0 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 0 of 0 included records.
Evidence data
Research landscape
Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.
Publication activity
Latest 12 represented yearsRecords by publication year
Evidence composition
Study designs
Transparency
Conflict-of-interest reporting
Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.
Abstract result signals
Extracted result direction
Research transparency
Funding and conflicts of interest
Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.
No funding agency was identified in the retrieved PubMed records.
01
Current Standard-of-Care Sources
Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.
No eligible guideline has been indexed in this snapshot.
The absence of a result is shown rather than filled from outside knowledge.
02
Highest-Priority Research
High-priority evidence has not been processed yet.
03
Latest Research — Last 24 Months
No recent records have been processed yet.
04
Treatment Options Studied in the PubMed Collection
These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.
Structured treatment extraction has not completed yet.
The background evidence pipeline will populate this section after PubMed retrieval and extraction.
05
Conflicting Research
No directly conflicting cluster has been identified yet.
This can mean the evidence is consistent, insufficient, or not detailed enough in the available abstracts to compare.
06
Failed or Negative Trials
No trial with a directly extractable failed/null primary finding has been processed yet.
07
Emerging and Experimental Research
No early-phase or preclinical record has been processed yet.
08
Evidence Gaps
No randomized or phase III evidence identified
The current PubMed collection does not contain a classified randomized or phase III study for this topic.
No PubMed-indexed guideline identified
Alexandria did not identify a guideline or consensus publication in the configured searches.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care60 records
Rank114.5
The APLAR Recommendations for the Management of Psoriatic Arthritis.
International journal of rheumatic diseases · 2025 · PMID 40725984
OBJECTIVES: Under the auspices of the Asia-Pacific League of Associations for Rheumatology (APLAR), we aimed to develop broad, evidence- and consensus-based guidelines to aid health professionals managing patients with psoriatic arthritis (PsA) in the region. METHODS: A working group of 35 members comprising rheumatologists, dermatologists, and patient research partners from 18 APLAR countries was convened. The working group conducted systematic literature reviews to derive the quality of evidence via GRADE methods…
Rank112.0
Guideline for the management of hepatitis B and C infection and subsequent liver disease surveillance (where indicated) in people with congenital bleeding disorders: A joint guideline from the British Society of Haematology and the British Viral Hepatitis Group.
British journal of haematology · 2026 · PMID 41431438
This is a new British Society of Haematology (BSH) guideline which focuses on the management of hepatitis B and C (HBV and HCV) infection affecting people with bleeding disorders (PwBD), including those who cleared the infection many years previously. It is based on the European Association for the Study of the Liver (EASL) guidance and is a succinct practical guide for haematologists to support joint care with hepatology. It is compatible with the joint international guidance from the European Association for Haem…
Rank110.0
Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations.
The Medical journal of Australia · 2025 · PMID 40976940
INTRODUCTION: Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, the sixth most common cause of cancer death in Australia. With shifting aetiologies and a growing at-risk population, consistent routine surveillance recommendations are key to early detection of HCC and improved survival. We developed new evidence-based HCC surveillance guidelines for people at high risk in Australia due to liver disease and/or other risk factors. These guidelines were developed by a working group of expe…
Rank110.0
AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review.
Gastroenterology · 2026 · PMID 42017860
DESCRIPTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in patients with cirrhosis. Although advancements in surgical, locoregional, and systemic therapies have improved outcomes for patients with early-stage HCC, most cases are diagnosed at later stages due to both the limitations of currently recommended surveillance modalities and their underuse, with fewer than 1 in 4 patients with cirrhosis receiving surveillance for this tumor. Current guidelines recommend semiannual surveillanc…
Rank110.0
[Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)].
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases · 2026 · PMID 42236454
Multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant tuberculosis (RR-TB) pose significant challenges to global tuberculosis prevention and treatment efforts. At present, the chemotherapy of MDR/RR-TB is still hampered by prolonged treatment duration and suboptimal success rates. In 2019, the Chinese Medical Association Tuberculosis Branch issued the Chinese Expert Consensus on the Treatment of MDR-TB and RR-TB, which has provided essential guidance for standardizing the diagnosis, treatment, and clin…
Rank110.0
British Association of Sexual Health and HIV guidelines on the management of viral hepatitis 2026.
International journal of STD & AIDS · 2026 · PMID 42117446
The 2026 British Association for Sexual Health and HIV (BASHH) guidelines for the management of viral hepatitis are in line with current evidence and practice within the United Kingdom. We provide evidence-based recommendations for the prevention, diagnosis and initial management of viral hepatitis A, B, C and D. Key updates are detailed at the start of the article.
Rank110.0
Management of Hepatitis B virus infection in patients on treatment with immunosuppressants or immunomodulators: Position Paper of Associazione Italiana Studio del Fegato (AISF), Associazione Italiana di Oncologia Medica (AIOM), Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Società Italiana di Reumatologia (SIR), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Gastroenterologia (SIGE), Società Italiana di Malattie Infettive e Tropicali (SIMIT).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025 · PMID 41219059
Immunosuppressants and immunomodulators are increasingly used for the treatment of several oncologic and immune-mediated diseases. However, reducing or inhibiting the immune system's activity can interfere with the natural mechanisms responsible for Hepatitis B Virus (HBV) control and may potentially induce HBV reactivation (HBVr) in both Hepatitis B surface Antigen (HBsAg) positive patients (overt infection) and HBsAg negative/anti-Hepatitis B core (anti-HBc) positive carriers. Among factors contributing to the pe…
Rank110.0
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.
Journal of hepatology · 2025 · PMID 40348683
The updated EASL Clinical Practice Guidelines on the management of hepatitis B virus (HBV) infection provide comprehensive, evidence-based recommendations for its management. Spanning ten thematic sections, the guidelines address diagnostics, treatment goals, treatment indications, therapeutic options, hepatocellular carcinoma surveillance, management of special populations, HBV reactivation prophylaxis, post-transplant care, HBV prevention strategies, and finally address open questions and future research directio…
Rank110.0
French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41469898
The current French guidelines for the treatment of psoriasis date from 2019 and do not include the most up-to-date interventions. The Psoriasis Research Group of the French Society of Dermatology has developed new guidelines to provide updated decision-making algorithms for the systemic treatment of adult patients with moderate-to-severe psoriasis. The algorithms were created following a thorough review of existing psoriasis treatment guidelines and recent publications on new systemic therapies not included in prev…
Rank110.0
Brazilian Society of Rheumatology - 2025 recommendations on vaccination in immune-mediated rheumatic diseases.
Advances in rheumatology (London, England) · 2026 · PMID 41578353
BACKGROUND: Patients with immune-mediated rheumatic diseases (IMRD) are at increased risk for infections due to both disease-related immune dysregulation and immunosuppressive therapy. Despite the benefits of vaccination, immunization rates in this population remain suboptimal, often due to concerns about safety, efficacy, and their potential for inducing disease flare. Regional-specific guidelines are necessary to address the particular epidemiological issues and aspects of the healthcare systems, especially in co…
Rank110.0
[Interpretation of key updates of the 2026 version of the APASL clinical practice guidelines for the management of chronic hepatitis B].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026 · PMID 42706035
The Asia-Pacific region has the heavy burden of chronic hepatitis B. In 2026, the Asia-Pacific Association for the Study of the Liver (APASL) updated its clinical practice guidelines for the management of chronic hepatitis B. The recommendations in this version of the guideline are formulated around focusing 13 core areas: vaccination and universal screening strategies, an established system of progressive treatment goals, pathways for stratified assessment of liver fibrosis based on resource availability, expansio…
Rank110.0
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.
Hepatology international · 2026 · PMID 42365189
Globally, especially in the Asia Pacific region, chronic hepatitis B infection has led to an undesirable escalating morbidity and mortality with acute-on chronic liver failure, end-staged liver cirrhosis, and hepatocellular carcinoma. This has happened despite the past four decades of major scientific advances made in screening methods, vaccination strategies, highly effective low-cost anti-viral therapies, and surveillance strategies for early detection of hepatocellular carcinoma. To address this health threat, A…
Rank110.0
Blood-Borne Infection Prevention in Combat Sports: Position Statement of the Association of Ringside Physicians.
Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine · 2026 · PMID 40197438
The Association of Ringside Physicians (ARP) emphasizes the importance of screening combat sports athletes for blood-borne infections, including hepatitis B, HIV, and hepatitis C, to mitigate transmission risks and ensure participant safety. Although transmission of hepatitis B and C and HIV in combat sports is rare, protecting athletes is of utmost importance. It is the recommendation of the ARP that all fighters participating in combat sports, in which the presence of blood is a common occurrence and is allowed d…
Rank110.0
[Chinese expert consensus on clinical practice of chronic hepatitis B functional (clinical) cure].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025 · PMID 41167769
Chronic hepatitis B functional (clinical) cure is currently an important therapeutic endpoint, which significantly reduces the incidence risk of cirrhosis and liver cancer. This expert consensus focuses on key clinical issues on the basis of previous studies, systematically elaborates population stratification and stepwise treatment strategies based on patient characteristics, consolidation therapy, relapse management, long-term monitoring after serum HBsAg clearance, and optimal management for patients who have no…
Rank110.0
AASLD ISDA Practice Guideline on treatment of chronic hepatitis B.
Hepatology (Baltimore, Md.) · 2026 · PMID 41186418
BACKGROUND AND AIMS: Accumulating data related to prevention, surveillance and treatment of chronic hepatitis B (CHB) provided the impetus for this updated guideline, using the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. METHODS: The guideline was developed in compliance with the National Academy of Medicine standards. The guideline panel developed structured questions following the Population, Intervention Comparison, Outcomes (PICO) framework. The panel addressed 6 PICO ques…
Rank110.0
Prevention, surveillance, and early detection of hepatocellular carcinoma - a Brazilian multidisciplinary consensus.
Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026 · PMID 42615769
BACKGROUND: Hepatocellular carcinoma is a major cause of cancer-related mortality and represents a growing public health challenge. AIMS: To develop multidisciplinary evidence-based recommendations for the prevention and early detection of hepatocellular carcinoma. METHODS: This consensus was coordinated by the Brazilian Society of Surgical Oncology, with the participation of 13 additional national societies. A steering committee defined the key clinical questions addressing prevention, surveillance, and early dete…
Rank108.0
Recommendations for the diagnosis of patients with hepatitis delta virus (HDV) in Spain.
Gastroenterologia y hepatologia · 2026 · PMID 42061813
The hepatitis delta virus (HDV), whose infection depends on the presence of the hepatitis B virus (HBV), is associated with one of the chronic viral hepatitis that most rapidly progresses to advanced liver disease, including liver cirrhosis and/or hepatocellular carcinoma. In this context, screening for HBV/HDV infection is key to the early diagnosis of hepatitis D, improving the prognosis of infected individuals through a strategy that has proven to be effective and efficient. This document reviews the epidemiolog…
Rank107.8
Etiology-related differences in hepatic recompensation in decompensated cirrhosis under Baveno VII criteria: a systematic review and meta-analysis.
BMC gastroenterology · 2026 · PMID 42420862
BACKGROUND: Decompensated cirrhosis has different causes. These causes differ in how they damage the liver, how difficult they are to treat, and how well they can be controlled. This may lead to different prevalences of recompensation. However, existing studies have failed to elucidate the heterogeneity of recompensation across different etiologies. Therefore, this study aimed to summarize differences in recompensation prevalence among decompensated cirrhosis etiologies according to the Baveno VII consensus, and to…
Rank107.0
Serum chloride concentrations and outcomes in adult patients with cirrhosis: a systematic review and meta-analysis.
BMC nephrology · 2025 · PMID 41013381
PURPOSE: Electrolyte disturbances, including hyponatremia, are common in cirrhosis, with hyponatremia already incorporated into the MELD-Na score as a prognostic marker. However, the prognostic role of serum chloride, the main extracellular anion, remains underexplored. Emerging evidence suggests hypochloremia is independently associated with increased mortality and acute kidney injury (AKI) in cirrhotic patients. Proposed mechanisms include dysregulated activation of the renin-angiotensin, vasopressin, and sympath…
Rank102.6
Evaluating Infections in Solid Organ Donors Before Transplantation: A Systematic Review of Clinical Practice Guidelines.
Transplantation · 2026 · PMID 41805905
BACKGROUND: Donor-derived infection remains a risk in solid organ transplantation. Clinical practice guidelines inform best practices for donor evaluation and acceptance, although they vary across centers and regions. This study aimed to evaluate the quality and consistency of guidelines for the evaluation of infections in solid organ donors and to summarize their recommendations. METHODS: We searched electronic databases and websites of professional organizations for clinical practice guidelines and consensus stat…
Rank102.0
Identifying barriers and facilitators to accessing harm reduction services in prisons: A systematic narrative synthesis.
The International journal on drug policy · 2025 · PMID 40517606
BACKGROUND: Drug use is prevalent in carceral settings globally. Although a comprehensive harm reduction package for people in prison (PIP) is recommended by international agencies, its implementation is limited. The aim of this systematic narrative synthesis was to explore barriers and facilitators to accessing harm reduction services (HRS) in prisons. METHODS: We searched MEDLINE, PsycINFO, SCOPUS, and CINAHL for English and French language articles published before June 26, 2024. Studies evaluating any HRS defin…
Rank100.0
Economic evaluation of hepatitis B screening in low- and middle-income countries: a systematic review.
International journal of clinical pharmacy · 2025 · PMID 40982118
INTRODUCTION: Hepatitis B virus (HBV) causes significant morbidity and mortality worldwide, particularly in low- and middle-income countries (LMICs) with intermediate to high endemicity. Screening interventions are essential for reducing infection rates. AIM: To synthesize economic evaluation evidence of hepatitis B (HBV) screening strategies in LMICs. METHOD: A comprehensive search of PubMed, Embase, and Scopus was conducted up to August 08, 2024. All types of economic evaluations comparing HBV screening strategie…
Rank96.0
Risk of hepatitis B virus reactivation associated with interleukin inhibitor therapies: protocol for a systematic review and meta-analysis.
BMJ open · 2025 · PMID 41213667
INTRODUCTION: The widespread application of interleukin (IL) inhibitors for various conditions, including gastrointestinal, rheumatologic, dermatologic and pulmonary diseases, has raised concerns regarding the potential for hepatitis B virus reactivation (HBVr). However, the precise risk of HBVr remains unclear due to inconsistencies in existing research. This systematic review aims to quantify the risk of HBVr in patients receiving IL inhibitor therapies. METHODS AND ANALYSIS: This systematic review will follow Pr…
Rank50.2
[Characteristics and predictive factors of recompensation in patients with hepatitis B-related decompensated cirrhosis: a retrospective cohort study].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026 · PMID 42706038
Objective: To investigate and evaluate the incidence rate, time distribution, related factors, and prediction model discriminative ability for recompensation in patients with hepatitis B-related decompensated cirrhosis. Methods: Four hundred and five patients hospitalized for the first time due to hepatitis B-related decompensated cirrhosis were retrospectively enrolled, using the date of initial hospitalization for decompensation as the follow-up initial point. Recompensation was defined as the resolution conditio…
Rank50.0
MRI of Hepatocellular Carcinoma: Cross-regional Perspectives on Trends and Opportunities.
Radiographics : a review publication of the Radiological Society of North America, Inc · 2026 · PMID 42658729
Management of hepatocellular carcinoma (HCC) can vary substantially by region. The authors highlight differences between Eastern and Western health care systems in the use of MRI for surveillance, diagnosis, and treatment monitoring in patients with HCC. These regional differences reflect variations in disease prevalence, treatment practice patterns, and reimbursement policies as well as the evolving role of MRI in the care continuum, for which global consensus has not yet been achieved. Although variations are not…
Evidence Syntheses60 records
Rank110.0
APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.
Hepatology international · 2026 · PMID 42365189
Globally, especially in the Asia Pacific region, chronic hepatitis B infection has led to an undesirable escalating morbidity and mortality with acute-on chronic liver failure, end-staged liver cirrhosis, and hepatocellular carcinoma. This has happened despite the past four decades of major scientific advances made in screening methods, vaccination strategies, highly effective low-cost anti-viral therapies, and surveillance strategies for early detection of hepatocellular carcinoma. To address this health threat, A…
Rank110.0
AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review.
Gastroenterology · 2026 · PMID 42017860
DESCRIPTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death in patients with cirrhosis. Although advancements in surgical, locoregional, and systemic therapies have improved outcomes for patients with early-stage HCC, most cases are diagnosed at later stages due to both the limitations of currently recommended surveillance modalities and their underuse, with fewer than 1 in 4 patients with cirrhosis receiving surveillance for this tumor. Current guidelines recommend semiannual surveillanc…
Rank110.0
[Chinese guideline for the chemotherapy of multidrug-resistant/rifampicin-resistant tuberculosis (2026 edition)].
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases · 2026 · PMID 42236454
Multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant tuberculosis (RR-TB) pose significant challenges to global tuberculosis prevention and treatment efforts. At present, the chemotherapy of MDR/RR-TB is still hampered by prolonged treatment duration and suboptimal success rates. In 2019, the Chinese Medical Association Tuberculosis Branch issued the Chinese Expert Consensus on the Treatment of MDR-TB and RR-TB, which has provided essential guidance for standardizing the diagnosis, treatment, and clin…
Rank110.0
An umbrella review navigating the nationwide burden of hepatitis B virus infection in Ethiopia: A call for action on vaccination, safe blood, and infection prevention.
PloS one · 2026 · PMID 42330006
BACKGROUND: The Hepatitis B virus (HBV) is one of the major causes of viral hepatitis that may persist and lead to complications, including cirrhosis, hepatic decompensation, and liver cancer. Numerous systematic reviews and meta-analysis have been conducted on HBV infection among people in Ethiopia, showing inconsistent findings. This umbrella review aimed to assess the pooled prevalence of HBV infection and its associated factors among people in Ethiopia. METHODS: All published and unpublished systematic review a…
Rank110.0
French guidelines on systemic treatments for moderate-to-severe psoriasis in adults: Update 2025.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2026 · PMID 41469898
The current French guidelines for the treatment of psoriasis date from 2019 and do not include the most up-to-date interventions. The Psoriasis Research Group of the French Society of Dermatology has developed new guidelines to provide updated decision-making algorithms for the systemic treatment of adult patients with moderate-to-severe psoriasis. The algorithms were created following a thorough review of existing psoriasis treatment guidelines and recent publications on new systemic therapies not included in prev…
Rank110.0
[Interpretation of key updates of the 2026 version of the APASL clinical practice guidelines for the management of chronic hepatitis B].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026 · PMID 42706035
The Asia-Pacific region has the heavy burden of chronic hepatitis B. In 2026, the Asia-Pacific Association for the Study of the Liver (APASL) updated its clinical practice guidelines for the management of chronic hepatitis B. The recommendations in this version of the guideline are formulated around focusing 13 core areas: vaccination and universal screening strategies, an established system of progressive treatment goals, pathways for stratified assessment of liver fibrosis based on resource availability, expansio…
Rank110.0
Prevention, surveillance, and early detection of hepatocellular carcinoma - a Brazilian multidisciplinary consensus.
Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2026 · PMID 42615769
BACKGROUND: Hepatocellular carcinoma is a major cause of cancer-related mortality and represents a growing public health challenge. AIMS: To develop multidisciplinary evidence-based recommendations for the prevention and early detection of hepatocellular carcinoma. METHODS: This consensus was coordinated by the Brazilian Society of Surgical Oncology, with the participation of 13 additional national societies. A steering committee defined the key clinical questions addressing prevention, surveillance, and early dete…
Rank110.0
British Association of Sexual Health and HIV guidelines on the management of viral hepatitis 2026.
International journal of STD & AIDS · 2026 · PMID 42117446
The 2026 British Association for Sexual Health and HIV (BASHH) guidelines for the management of viral hepatitis are in line with current evidence and practice within the United Kingdom. We provide evidence-based recommendations for the prevention, diagnosis and initial management of viral hepatitis A, B, C and D. Key updates are detailed at the start of the article.
Rank109.7
Global Underutilization of Antiviral Therapy and Survival Outcomes in Hepatitis B Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of 78 Studies and 68,243 Patients.
Journal of viral hepatitis · 2026 · PMID 42876044
Antiviral therapy with nucleos(t)ide analogues is recommended for patients with viremic hepatitis B virus (HBV)-related cirrhosis regardless of levels of viremia or liver enzymes. However, hepatocellular carcinoma (HCC) is not an antiviral treatment criterion in the U.S. HBV treatment guidelines, though prior studies have reported improved survival with antiviral treatment in HBV-related HCC. To inform guidelines, we estimated antiviral treatment rates and their association with survival and HCC recurrence rates in…
Rank108.6
Seroprevalence and Molecular Epidemiology of Hepatitis B and D Viruses in Mauritania: a Systematic Review and Meta-Analysis.
Journal of epidemiology and global health · 2026 · PMID 41996018
Mauritania has a high prevalence of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV), posing a major public health burden. A comprehensive analysis of seroprevalence, transmission dynamics, and molecular epidemiology would help inform strategies for public health interventions. This study systematically reviews the published literature in the field between 1983 and 2024, employing PRISMA 2020 guidelines. Where insufficient data were available for meta-analyses on specific inquiries, summative description…
Rank108.3
Efficacy and safety of clipping prior to cyanoacrylate embolization in gastric varices: a single-arm systematic review and meta-analysis.
Surgical endoscopy · 2026 · PMID 42377512
BACKGROUND: Gastric variceal bleeding is a life-threatening complication of portal hypertension. Cyanoacrylate injection is the standard endoscopic treatment that carries a significant risk of ectopic embolization, particularly in patients with gastrorenal shunts. Adding endoscopic clips before injection may enhance safety and efficacy, yet evidence remains limited. This study evaluates the safety and effectiveness of clip-assisted cyanoacrylate injection (clip-ECI). METHODOLOGY: A systematic search was conducted o…
Rank108.0
Recommendations for the diagnosis of patients with hepatitis delta virus (HDV) in Spain.
Gastroenterologia y hepatologia · 2026 · PMID 42061813
The hepatitis delta virus (HDV), whose infection depends on the presence of the hepatitis B virus (HBV), is associated with one of the chronic viral hepatitis that most rapidly progresses to advanced liver disease, including liver cirrhosis and/or hepatocellular carcinoma. In this context, screening for HBV/HDV infection is key to the early diagnosis of hepatitis D, improving the prognosis of infected individuals through a strategy that has proven to be effective and efficient. This document reviews the epidemiolog…
Rank108.0
Finite Versus Indefinite Nucleos(t)ide Analogue Therapy in HBeAg‑Negative Chronic Hepatitis B: Meta‑Analysis of Randomized Trials.
Journal of viral hepatitis · 2026 · PMID 42834661
Continuous nucleos(t)ide analogue (NA) therapy for chronic hepatitis B (CHB) effectively maintains viral suppression but rarely results in functional cure. Finite NA therapy has been proposed to increase rates of HBsAg loss; however, international guidelines provide conflicting recommendations. This study compares the efficacy and safety of finite versus continuous NA therapy in HBeAg-negative adults using randomized controlled trials. We included parallel-group randomized controlled trials (RCTs) comparing nucleos…
Rank107.8
Etiology-related differences in hepatic recompensation in decompensated cirrhosis under Baveno VII criteria: a systematic review and meta-analysis.
BMC gastroenterology · 2026 · PMID 42420862
BACKGROUND: Decompensated cirrhosis has different causes. These causes differ in how they damage the liver, how difficult they are to treat, and how well they can be controlled. This may lead to different prevalences of recompensation. However, existing studies have failed to elucidate the heterogeneity of recompensation across different etiologies. Therefore, this study aimed to summarize differences in recompensation prevalence among decompensated cirrhosis etiologies according to the Baveno VII consensus, and to…
Rank107.7
Risk factors for postpartum alanine aminotransferase elevation in women with chronic hepatitis B infection: a systematic review and meta-analysis.
Frontiers in public health · 2026 · PMID 42953154
BACKGROUND: Postpartum alanine aminotransferase (ALT) elevation is common in women with chronic hepatitis B (CHB) infection and may adversely affect maternal recovery and long-term disease outcomes. However, the risk factors associated with postpartum ALT elevation remain inconsistent across studies. METHODS: We conducted a systematic review and meta-analysis in accordance with the PRISMA guidelines; the registration number is CRD420251208005. PubMed, Web of Science, Embase, Cochrane Library, China National Knowled…
Rank107.7
First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety.
Frontiers in immunology · 2026 · PMID 42220514
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the front-line treatment of advanced hepatocellular carcinoma (HCC). However, the comparative efficacy and safety of different ICI-based regimens-and their consistency across etiologic subgroups [HBV, HCV, and non-HBV/non-HCV (NBNC)]-remain uncertain. This study conducted a Bayesian network meta-analysis (NMA) of recent randomized controlled trials (RCTs) to compare the first-line immunotherapy strategies both overall and by viral etiology. METHODS…
Rank107.5
Effectiveness of Digital Health Interventions to Improve Self-Care in Patients With Chronic Diseases: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Journal of medical Internet research · 2026 · PMID 42263266
BACKGROUND: Chronic diseases account for most global morbidity and mortality, increasing the need for effective long-term self-care support. Digital health interventions, such as mobile apps, telemonitoring, and connected devices, are increasingly used to promote self-care; yet, their overall effectiveness across chronic conditions remains unclear. OBJECTIVE: This systematic review and meta-analysis evaluated whether digital health interventions improve self-care in adults with chronic diseases. METHODS: We searche…
Rank107.3
Viral hepatitis co-infections with tuberculosis in India: A systematic review and meta-analysis.
The Indian journal of medical research · 2026 · PMID 42295712
Background and objectives Tuberculosis (TB) and viral hepatitis (hepatitis B and C) co-infection is a significant threat in low-and middle-income countries like India. To optimise treatment protocols and prevent liver-related complications, it is essential to estimate the burden of these co-infections. This systematic review and meta-analysis were conducted to determine the prevalence of hepatitis B and C co-infection with tuberculosis in India. Methods In line with PRISMA guidelines, a systematic search of PubMed,…
Rank106.8
Efficacy and safety of Tenofovir disoproxil fumarate (TDF) or Entecavir (ETV) combined with interferon for the treatment of chronic hepatitis B: a systematic review and meta-analysis.
Virology journal · 2026 · PMID 42919405
BACKGROUND: Whether tenofovir disoproxil fumarate (TDF) or entecavir (ETV) combined with pegylated interferon offers superior functional cure potential in chronic hepatitis B remains unclear. OBJECTIVE: To compare the efficacy and safety of TDF plus interferon versus ETV plus interferon against their respective monotherapies. METHODS: Systematic review and meta-analysis of 16 randomized controlled trials from six databases (inception to January 2026). INTERVENTIONS: TDF (300 mg/day) or ETV (0.5 mg/day) plus pegylat…
Rank106.7
Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis.
BMC infectious diseases · 2026 · PMID 42288778
OBJECTIVE: To evaluate the efficacy and safety of antiretroviral therapy(ART) regimens based on tenofovir(TDF) + lamivudine(3TC) + efavirenz(EFV) in patients co-infected with Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV), thereby providing evidence-based support for clinical treatment decision-making. METHODS: Relevant studies published from database inception to March 2025 were systematically retrieved from the CNKI, Wanfang, VIP, SinoMed, PubMed, Embase, Web of Science, and Cochrane Library datab…
Rank106.0
Thymosin-ɑ1 for people with chronic hepatitis B.
The Cochrane database of systematic reviews · 2026 · PMID 42713852
RATIONALE: Chronic hepatitis B is a global public health concern. It is caused by infection with the hepatitis B virus (HBV). The goal of treating chronic HBV infection is to prevent progression to chronic hepatitis, cirrhosis, hepatic decompensation, liver failure, hepatocellular carcinoma, and death. Individual studies have evaluated various immunomodulatory therapies with inconsistent results. Thymosin-ɑ1 is known to have antiviral effects; however, results of randomised clinical trials on the effects of thymosi…
Rank105.9
Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis.
Liver international : official journal of the International Association for the Study of the Liver · 2026 · PMID 42287020
BACKGROUND AND AIMS: This study aimed to determine the incidence of hepatitis B virus reactivation (HBVr) in patients with chronic or occult HBV infection who were treated with IL-12/23, IL-23 (together referred to as anti-IL-23/12), IL-17, or JAK inhibitors without antiviral prophylaxis. In addition, we sought to assess whether the risk of HBVr varies according to anti-HBs status among individuals who are anti-HBc positive. METHODS: A systematic review and meta-analysis were conducted in accordance with PRISMA and…
Rank105.5
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).
Gut · 2026 · PMID 41198171
BACKGROUND: Peg-interferon (peg-IFN) plays an increasingly important role in HBV cure strategies, either in combination with novel antivirals, as a lead-in or as consolidation treatment. OBJECTIVE: We aimed to provide estimates of hepatitis B surface antigen (HBsAg) decline and clearance that can be achieved with peg-IFN addition to nucleos(t)ide analogue (NA) therapy. DESIGN: This is a post hoc meta-analysis of individual participant data from eight clinical trials involving chronic hepatitis B patients on NA ther…
Rank102.6
Evaluating Infections in Solid Organ Donors Before Transplantation: A Systematic Review of Clinical Practice Guidelines.
Transplantation · 2026 · PMID 41805905
BACKGROUND: Donor-derived infection remains a risk in solid organ transplantation. Clinical practice guidelines inform best practices for donor evaluation and acceptance, although they vary across centers and regions. This study aimed to evaluate the quality and consistency of guidelines for the evaluation of infections in solid organ donors and to summarize their recommendations. METHODS: We searched electronic databases and websites of professional organizations for clinical practice guidelines and consensus stat…
Rank100.0
Interventions to Increase Hepatitis B Testing Uptake Amongst Detained Populations: A Systematic Review.
Journal of viral hepatitis · 2026 · PMID 42163587
People who have been detained have a higher prevalence of hepatitis B virus (HBV) than the general population, yet testing uptake remains limited. Improving testing uptake in high-risk settings is essential to the World Health Organization 2030 elimination target. This systematic review examines interventions aimed at increasing hepatitis B testing uptake in prison. MEDLINE, EMBASE, CENTRAL and CINAHL were searched from January 2000 to April 2025. Quantitative interventional studies were included. Quality appraisal…
Randomized Controlled Trials60 records
Rank108.3
Efficacy and safety of clipping prior to cyanoacrylate embolization in gastric varices: a single-arm systematic review and meta-analysis.
Surgical endoscopy · 2026 · PMID 42377512
BACKGROUND: Gastric variceal bleeding is a life-threatening complication of portal hypertension. Cyanoacrylate injection is the standard endoscopic treatment that carries a significant risk of ectopic embolization, particularly in patients with gastrorenal shunts. Adding endoscopic clips before injection may enhance safety and efficacy, yet evidence remains limited. This study evaluates the safety and effectiveness of clip-assisted cyanoacrylate injection (clip-ECI). METHODOLOGY: A systematic search was conducted o…
Rank108.0
Finite Versus Indefinite Nucleos(t)ide Analogue Therapy in HBeAg‑Negative Chronic Hepatitis B: Meta‑Analysis of Randomized Trials.
Journal of viral hepatitis · 2026 · PMID 42834661
Continuous nucleos(t)ide analogue (NA) therapy for chronic hepatitis B (CHB) effectively maintains viral suppression but rarely results in functional cure. Finite NA therapy has been proposed to increase rates of HBsAg loss; however, international guidelines provide conflicting recommendations. This study compares the efficacy and safety of finite versus continuous NA therapy in HBeAg-negative adults using randomized controlled trials. We included parallel-group randomized controlled trials (RCTs) comparing nucleos…
Rank107.7
First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safety.
Frontiers in immunology · 2026 · PMID 42220514
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the front-line treatment of advanced hepatocellular carcinoma (HCC). However, the comparative efficacy and safety of different ICI-based regimens-and their consistency across etiologic subgroups [HBV, HCV, and non-HBV/non-HCV (NBNC)]-remain uncertain. This study conducted a Bayesian network meta-analysis (NMA) of recent randomized controlled trials (RCTs) to compare the first-line immunotherapy strategies both overall and by viral etiology. METHODS…
Rank107.5
Effectiveness of Digital Health Interventions to Improve Self-Care in Patients With Chronic Diseases: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Journal of medical Internet research · 2026 · PMID 42263266
BACKGROUND: Chronic diseases account for most global morbidity and mortality, increasing the need for effective long-term self-care support. Digital health interventions, such as mobile apps, telemonitoring, and connected devices, are increasingly used to promote self-care; yet, their overall effectiveness across chronic conditions remains unclear. OBJECTIVE: This systematic review and meta-analysis evaluated whether digital health interventions improve self-care in adults with chronic diseases. METHODS: We searche…
Rank106.8
Efficacy and safety of Tenofovir disoproxil fumarate (TDF) or Entecavir (ETV) combined with interferon for the treatment of chronic hepatitis B: a systematic review and meta-analysis.
Virology journal · 2026 · PMID 42919405
BACKGROUND: Whether tenofovir disoproxil fumarate (TDF) or entecavir (ETV) combined with pegylated interferon offers superior functional cure potential in chronic hepatitis B remains unclear. OBJECTIVE: To compare the efficacy and safety of TDF plus interferon versus ETV plus interferon against their respective monotherapies. METHODS: Systematic review and meta-analysis of 16 randomized controlled trials from six databases (inception to January 2026). INTERVENTIONS: TDF (300 mg/day) or ETV (0.5 mg/day) plus pegylat…
Rank106.7
Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis.
BMC infectious diseases · 2026 · PMID 42288778
OBJECTIVE: To evaluate the efficacy and safety of antiretroviral therapy(ART) regimens based on tenofovir(TDF) + lamivudine(3TC) + efavirenz(EFV) in patients co-infected with Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV), thereby providing evidence-based support for clinical treatment decision-making. METHODS: Relevant studies published from database inception to March 2025 were systematically retrieved from the CNKI, Wanfang, VIP, SinoMed, PubMed, Embase, Web of Science, and Cochrane Library datab…
Rank106.0
Thymosin-ɑ1 for people with chronic hepatitis B.
The Cochrane database of systematic reviews · 2026 · PMID 42713852
RATIONALE: Chronic hepatitis B is a global public health concern. It is caused by infection with the hepatitis B virus (HBV). The goal of treating chronic HBV infection is to prevent progression to chronic hepatitis, cirrhosis, hepatic decompensation, liver failure, hepatocellular carcinoma, and death. Individual studies have evaluated various immunomodulatory therapies with inconsistent results. Thymosin-ɑ1 is known to have antiviral effects; however, results of randomised clinical trials on the effects of thymosi…
Rank100.9
A 7-mm Covered TIPS Reduces Hepatic Encephalopathy Without Increasing Rebleeding in Cirrhotic Patients With Small Liver: A Randomized Study.
Liver international : official journal of the International Association for the Study of the Liver · 2026 · PMID 42723205
BACKGROUND/AIMS: International guidelines recommend initiating transjugular intrahepatic portosystemic shunt (TIPS) placement with an 8-mm stent. However, there is an evident lack of randomized controlled trials evaluating TIPS diameters < 8 mm in cirrhotic patients with a relatively small liver. The aim of this study was to determine whether 7 mm-covered TIPS, compared with 8-mm stents, could achieve comparable shunt function with a lower incidence of hepatic encephalopathy (HE). METHODS: In this multicenter rando…
Rank100.0
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil in chronic hepatitis b: a systematic review and meta-analysis of randomized controlled trials.
BMC infectious diseases · 2026 · PMID 42410542
BACKGROUND: In treating Chronic Hepatitis B (CHB), tenofovir disoproxil fumarate (TDF) carries risks like renal toxicity and reduced bone mineral density (BMD). TAF, the next-generation prodrug of TFV, is more stable in plasma than TDF, requires a significantly lower dose (25 mg vs. 300 mg), and results in approximately 90% lower plasma TFV levels, contributing to a more favorable renal and bone safety profile. This study aimed to evaluate the efficacy and safety of tenofovir alafenamide fumarate (TAF) compared to …
Rank100.0
Efficacy of antiviral therapy in adults with chronic hepatitis B according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis.
The lancet. Gastroenterology & hepatology · 2026 · PMID 41839198
BACKGROUND: In the 2015 WHO guidelines for chronic hepatitis B (CHB), antiviral therapy was recommended for individuals with cirrhosis and individuals without cirrhosis with persistently elevated alanine aminotransferase (ALT) concentrations and hepatitis B virus (HBV) DNA >20 000 IU/mL, whereas treatment was deferred for individuals with persistently normal ALT concentrations and HBV DNA <2000 IU/mL. To inform 2024 WHO guidelines on CHB and the potential expansion of treatment threshold recommendations, we conduct…
Rank100.0
Natural history of chronic hepatitis B in untreated adults without cirrhosis according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis.
The lancet. Gastroenterology & hepatology · 2026 · PMID 41839199
BACKGROUND: Chronic hepatitis B (CHB) affects an estimated 254 million people globally. Historically, WHO and professional society guidelines have recommended treatment for individuals at high risk of disease progression, including those with hepatitis B virus (HBV) DNA concentrations >20 000 IU/mL. Whether individuals at lower risk, including those with HBV DNA <20 000 IU/mL and normal alanine aminotransferase concentrations, benefit from treatment remains uncertain. To inform 2024 WHO guidelines and the potential…
Rank99.5
Efficacy and Safety of Switching from Entecavir to Tenofovir Alafenamide in Chronic Hepatitis B: A Multicenter Randomized Trial in Korea.
Gut and liver · 2026 · PMID 42015653
BACKGROUND/AIMS: Tenofovir alafenamide (TAF) has emerged as a safe and effective alternative to entecavir (ETV) in the management of chronic hepatitis B (CHB). We aimed to evaluate the efficacy and safety of switching to TAF compared with maintaining ETV in patients with CHB who had achieved virologic suppression on ETV. METHODS: In this multicenter, randomized, open-label, active-controlled, noninferiority clinical trial conducted at 13 Korean centers, 196 CHB patients who had experienced virologic suppression aft…
Rank99.2
Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial.
Hepatology international · 2026 · PMID 42213313
OBJECTIVES: The objective of this study was to investigate the efficacy and safety of oral tolvaptan for hyponatremia in patients with cirrhosis in China. PATIENTS AND METHODS: In this post hoc subgroup analysis of a phase 2 clinical trial of oral tolvaptan for hyponatremia due to cirrhosis, heart failure, and syndrome of inappropriate antidiuretic hormone secretion in China, patients with hyponatremia due to cirrhosis received placebo or tolvaptan for 7 days (15 mg titrated to 30 or 60 mg/day). The primary endpoin…
Rank99.0
[Clinical study on the efficacy of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia patients with chronic hepatitis B].
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026 · PMID 42373438
Objective: To comprehensively evaluate the efficacy and safety profile of Wuling capsules combined with nucleos(t)ide analogues in the treatment of low-level viremia in chronic hepatitis B. Methods: A randomized, controlled, multicenter clinical trial was conducted. One hundred patients with low-level viremia in chronic hepatitis B admitted between December 2021 and March 2024 were randomly divided into an experimental group and a control group, with 50 cases in each group. The experimental group received nucleos(t…
Rank98.9
Efficacy of dolutegravir/lamivudine in adults with HIV-1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results.
HIV medicine · 2026 · PMID 41992416
OBJECTIVES: As two-drug HIV-1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti-HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three- or four-drug regimens (3DRs/4DRs) among people with HIV-1 and isolated reactive anti-HBc. METHODS: Data were evaluated from GEMINI-1, GEMINI-2, STAT, TANGO and SALSA at various time points, including Weeks 48, 96…
Rank98.6
Safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in USA and Puerto Rico: Results from a Phase III, randomized, active-controlled study.
Human vaccines & immunotherapeutics · 2026 · PMID 42642862
MenACYW-TT, a quadrivalent meningococcal tetanus toxoid-conjugate vaccine, is approved for prevention of invasive meningococcal disease in infants ≥ 6 weeks of age in the USA. This Phase III study (NCT03673462; September 17, 2018 - March 16, 2023) evaluated the safety of MenACYW-TT compared with a licensed quadrivalent meningococcal oligosaccharide diphtheria CRM197-conjugate vaccine (MenACWY-CRM) when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in a four-dose series (…
Rank98.1
A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B.
Hepatology (Baltimore, Md.) · 2026 · PMID 41945711
BACKGROUND AND AIMS: Pradefovir mesylate is a novel liver-targeting prodrug of adefovir developed using HepDirect technology. We report that the phase 3 trial is to compare the efficacy and safety of pradefovir versus tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB). APPROACH AND RESULTS: This ongoing randomized, double-blind, non-inferiority, phase 3 study was conducted at 58 sites in China. Patients with CHB were randomly assigned (2:1) to receive either 45 mg daily pradefovir or 300…
Rank98.0
Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial.
Transplantation and cellular therapy · 2026 · PMID 42150672
Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with resolved HBV infection undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Although HBV DNA-guided preemptive nucleos(t)ide analog therapy prevents HBV-related hepatitis, strategies to prevent HBV reactivation itself remain limited. Hepatitis B vaccination after allo-HCT has been suggested as a potential preventive strategy, but prospective randomized evidence is lacking. To evaluate whether hepatitis B (HepB) v…
Rank97.9
Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.
The Lancet. Infectious diseases · 2026 · PMID 41865748
BACKGROUND: Few data are available comparing the WHO diphtheria-tetanus-pertussis (DTP)-containing vaccine schedule with reduced-dose or delayed three-dose schedules in infants. We aimed to identify an alternative schedule that is non-inferior or superior to the WHO schedule in maintaining early pertussis antibody levels before booster, while creating space for integration of new vaccines. METHODS: In two parallel, open-label, randomised, non-inferiority trials in Uganda and Nepal, healthy infants aged 42-50 days w…
Rank97.6
Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.
The New England journal of medicine · 2026 · PMID 42206582
BACKGROUND: Treatment with bepirovirsen, an antisense oligonucleotide targeting hepatitis B virus (HBV) transcripts, has the potential to result in a functional cure, defined by at least 24 weeks of a sustained HBV DNA level below the lower limit of quantification (LLOQ) and hepatitis B surface antigen (HBsAg) loss after fixed-duration therapy. METHODS: In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcuta…
Rank97.4
Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · PMID 40953786
BACKGROUND & AIMS: Nucleos(t)ide analogue (NAs) discontinuation promotes hepatitis B surface antigen (HBsAg) clearance among European patients with chronic hepatitis B virus (HBV) infection. The efficacy and safety of a novel HBV biomarker-guided NAs withdrawal strategy among Asian patients was evaluated in this multicenter randomized controlled trial. METHODS: NAs-experienced patients achieving HBsAg <200 IU/mL and undetectable HBV DNA for ≥12 months with HBV RNA or hepatitis core-related antigen undetectable were…
Rank97.3
Short-cycle 4-days-per-week maintenance two-drug therapy in people living with HIV (ANRS-177 DUETTO): a randomised, open-label, multicentre, non-inferiority trial.
The lancet. HIV · 2026 · PMID 42140217
BACKGROUND: Previous trials have validated the strategy of short-cycle three-drug (triple) antiretroviral therapy for HIV treatment. The main objective of ANRS-177 DUETTO was to assess whether a two-drug (dual) regimen taken on 4 consecutive days per week (4/7-days) was virologically non-inferior to standard dual therapy regimen taken 7 days per week (7/7-days) in participants with HIV and sustained viral suppression. METHODS: This open-label, randomised, parallel, multicentre, non-inferiority trial enrolled adults…
Rank97.2
Impact of resolved hepatitis B virus infection on clinical outcomes in patients with diffuse large B-cell lymphoma: a supplementary analysis of JCOG0601.
International journal of hematology · 2026 · PMID 42801438
The impact of resolved hepatitis B virus (HBV) infection, defined as pretreatment hepatitis B surface antigen (HBsAg) negativity with antibody to hepatitis B core antigen (anti-HBc) positivity, on the clinical characteristics and outcomes of diffuse large B-cell lymphoma (DLBCL) remains unclear. JCOG0601 was a randomized phase II/III trial showing no improvement in progression-free survival (PFS) with dose-dense rituximab plus CHOP in previously untreated DLBCL. This supplementary analysis of JCOG0601 evaluated whe…
Rank96.5
The small interfering RNA imdusiran as single and multiple doses in healthy, randomised individuals and non-randomised individuals with chronic hepatitis B (AB-729-001): a phase 1a/b trial.
The lancet. Gastroenterology & hepatology · 2026 · PMID 42173110
BACKGROUND: Functional cure of chronic hepatitis B requires a sustained loss of HBsAg and hepatitis B virus (HBV) DNA, which is unlikely with current therapies. We aimed to investigate the safety, antiviral activity, and anti-HBV immune responses of the N-acetylgalactosamine-conjugated, small interfering RNA imdusiran, a therapeutic strategy designed to reduce viral antigens on the path to achieving immune control. METHODS: AB-729-001 was a phase 1a/b trial conducted at 11 centres and hospitals: three in Australia,…
Rank96.4
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial.
Journal of hepatology · 2026 · PMID 41966308
BACKGROUND & AIMS: Bulevirtide is approved in several countries and regions for the treatment of compensated chronic hepatitis D (CHD). However, long-term outcomes after treatment discontinuation remain unknown. METHODS: Patients with CHD (n = 150) were randomized to immediate treatment with bulevirtide 2 mg/day (n = 49) or 10 mg/day (n = 50) for 144 weeks (W), or a 48W delay before starting treatment (DT; n = 51) followed by bulevirtide 10 mg/day for 96W (DT/10 mg; n = 50), and 96W of post-treatment follow-up (FU9…
i
Research information notice
Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.